Drug Information

Drug General Information
Drug ID
D03KOZ
Former ID
DAP001376
Drug Name
Epalrestat
Synonyms
Epalrestatum; Kinedak; Epalrestat [INN]; Epalrestatum [Latin]; ONO 2; Ono 2235; Aldorin (TN); Kinedak (TN); ONO-2; Ono-2235; Epalrestat (JAN/INN); {5-[(E)-2-Methyl-3-phenyl-prop-2-en-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; 2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid; 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid; 3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine; 5-((1Z,2E)-2-Methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; 5-((Z,E)-beta-Methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid
Drug Type
Small molecular drug
Indication Diabetic neuropathy [ICD9: 250, 250.6, 356.0, 356.8; ICD10:E11.40] Approved [536361]
Therapeutic Class
Hypoglycemic Agents
Company
Eskayef Bangladesh Limited
Structure
Download
2D MOL

3D MOL
Formula
C15H13NO3S2
Canonical SMILES
CC(=CC1=CC=CC=C1)C=C2C(=O)N(C(=S)S2)CC(=O)O
InChI
1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
InChIKey
CHNUOJQWGUIOLD-NFZZJPOKSA-N
CAS Number
CAS 82159-09-9
PubChem Compound ID
1549120
PubChem Substance ID
7848751, 8653343, 12012832, 14826092, 26664249, 26758035, 32249007, 50052031, 57409089, 57974228, 79306115, 81092897, 85171753, 87932284, 103245600, 103980041, 104822630, 110525354, 117664431, 125126796, 126684126, 130673647, 134223203, 134338587, 135026827, 135692379, 136374773, 136946437, 137249280, 137267392, 142773098, 143404361, 143970327, 144115945, 162035741, 162177691, 164196566, 172089065, 172120909, 174478174, 175267046, 179151242, 184015922, 184545249, 184816928, 188628128, 210276582, 210281429, 223381370, 223434916
Target and Pathway
Target(s) Aldose reductase Target Info Inhibitor [535244], [537989]
BioCyc Pathway Methylglyoxal degradation III
Acetone degradation I (to methylglyoxal)
KEGG Pathway Pentose and glucuronate interconversions
Fructose and mannose metabolism
Galactose metabolism
Glycerolipid metabolism
Metabolic pathways
NetPath Pathway IL1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
PathWhiz Pathway Fructose and Mannose Degradation
Pyruvate Metabolism
Pterine Biosynthesis
Glycerolipid Metabolism
Galactose Metabolism
WikiPathways Metapathway biotransformation
Polyol Pathway
Metabolism of steroid hormones and vitamin D
References
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 535244Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
Ref 537989Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications. 1996 May-Jun;10(3):168-72.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.